Clinical Edge Journal Scan

Interval BC have more unfavorable characteristics than screen-detected BC


 

Key clinical point: Interval breast cancers (BC) detected between annual mammograms have significantly worse prognostic characteristics than BC detected during mammographic screening.

Major finding: Breast density is significantly associated with the development of an interval cancer (adjusted odds ratio 2.17; P = .003). Interval vs screen-detected BC were more often primary tumor stage II or higher (43% vs 12%; P < .001), regional lymph node stage I or higher (22% vs 12%; P = .003), triple negative (21% vs 6%; P < .001) with high Ki67 proliferation indices (62% vs 38%; P = .002), and significantly more invasive ( P = .007).

Study details: Findings are from a retrospective cohort study including 1232 women diagnosed with BC within 1 year of screening, of which 1136 had screen-detected BC and 96 had interval BC.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Ambinder EB et al. Interval breast cancers versus screen detected breast cancers: A retrospective cohort study. Acad Radiol. 2023 (Feb 3). Doi: 10.1016/j.acra.2023.01.007

Recommended Reading

Progress in breast cancer screening over the past 50 years: A remarkable story, but still work to do
Breast Cancer ICYMI
‘Financial toxicity’ from breast cancer is a worldwide phenomenon
Breast Cancer ICYMI
Real-world survival benefit with CDK4/6 inhibitors in MBC
Breast Cancer ICYMI
Adjuvant AI yields better survival outcomes than tamoxifen or tamoxifen+AI in HR+/HER2+ BC
Breast Cancer ICYMI
Contralateral prophylactic mastectomy offers no survival advantage in TNBC
Breast Cancer ICYMI
SPIO can help avoid upfront sentinel lymph node dissection in ductal carcinoma in situ of the breast
Breast Cancer ICYMI
Adding ET to dual anti-HER2 targeted therapy beneficial in HER2+/HR+ metastatic BC
Breast Cancer ICYMI
Adjuvant abemaciclib+ET shows treatment benefit regardless of menopausal status in HR+/HER2− early BC
Breast Cancer ICYMI
High PD-L2 levels may predict worse clinical outcomes in ER+ BC
Breast Cancer ICYMI
Risk for local recurrence higher in microinvasive vs T1a-2 BC
Breast Cancer ICYMI